107017-72-1 Usage
General Description
1-AMINO-CYCLOPROPANEMETHANOL, also known as 1-Aminocyclopropanemethanol, is a chemical compound with the molecular formula C4H9NO. It is a cyclic compound containing a three-membered ring of carbon atoms with an amino group and a hydroxyl group attached to it. 1-AMINO-CYCLOPROPANEMETHANOL is used as a building block in organic synthesis and is a precursor to various pharmaceuticals and agrochemicals. It has been studied for its potential pharmaceutical applications, including as an antihypertensive and as a treatment for respiratory diseases. Additionally, it has been investigated for its potential use as a chiral auxiliary in asymmetric synthesis. Overall, 1-AMINO-CYCLOPROPANEMETHANOL is a versatile chemical compound with potential applications in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 107017-72-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,7,0,1 and 7 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 107017-72:
(8*1)+(7*0)+(6*7)+(5*0)+(4*1)+(3*7)+(2*7)+(1*2)=91
91 % 10 = 1
So 107017-72-1 is a valid CAS Registry Number.
InChI:InChI=1/C4H9NO/c5-4(3-6)1-2-4/h6H,1-3,5H2
107017-72-1Relevant articles and documents
Evidence for a Radical Mechanism in Cu(II)-Promoted SnAP Reactions
Luescher, Michael U.,Bode, Jeffrey W.
, p. 464 - 470 (2019)
Saturated nitrogen heterocycles can be found with increasing abundance in bioactive molecules despite a limited number of methods to access these scaffolds. However, the coupling of recently introduced SnAP [tin (Sn) amine protocol] reagents with a wide r
FUSED RING COMPOUNDS
-
Paragraph 0851, (2020/06/01)
This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
Paragraph 1692, (2017/05/14)
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
